Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

180 Applying Pharmacogenomics in Therapeutics
95. Gilotrif [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc;
2014.
96. Tarceva [package insert]. South San Francisco, CA: Genentech, Inc; 2015.
97. Rosell R, Cancereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as
first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell
lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 2012;13(3):239.
98. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-smallcell
lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889.
99. Xalkori [package insert]. New York, NY: Pfizer; 2013.
100. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced
ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385.
101. Zykadia [package insert]. East Hanover, NJ: Novartis Pharmaceutical; 2014.
102. K378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged
Non-small Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT01828099?term=
NCT01828099&rank=1 (accessed April 27, 2015).
103. LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously
Treated With Chemotherapy (Platinum Doublet) and Crizotinib. https://clinicaltrials.
gov/ct2/show/NCT01828112?term=NCT01828112&rank=1 (accessed April 27, 2015).
104. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALKrearranged
advanced non-small-cell lung cancer (AF-001JP study): A single-arm,
open-label, phase 1-2 study. Lancet Oncol. 2013;14(7):590.
105. De Braekeleer E, Douet-Guilbert N, Rowe D, et al. ABL1 fusion genes in hematological
malignancies: A review. Eur J Haemotol. 2011;86(5):361–71.
106. Terasawa T, Dahabreh I, Trikalinos T. BCR-ABL mutation testing to predict response
to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. PLoS Curr
Evid Genomic Tests. 2011;2:RRN1204. doi: 10.1371/currents.RRN1204.
107. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I:
From the second to third generation. Expert Rev Anticancer Ther. 2008;8(9):1387–98.
108. Bosulif [package insert]. New York, NY: Pfizer Labs; 2014.
109. Iclusig [package insert]. Cambridge, MA: Ariad Pharmaceuticals; 2015.
110. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507.
111. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;​
380(9839):358.
112. Mekinist [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014.
113. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in
BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.
114. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in
patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
115. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2015.
116. Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015.
117. Robert C, Ribas A, Wolchok JD. Anti-programmed-death-receptor-1 treatment with
pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dosecomparison
cohort of a phase 1 trial. Lancet. 2014;384:1109–17.
118. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without
BRAF mutation. N Engl J Med. 2015;372:320–30.
119. Ekhart C, Rodenhuis S, Smits PHM, et al. Relations between polymorphisms in drugmetabolising
enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa,
and carboplatin. Pharmacogenet Genomics. 2008;18(11):1009–15.